BRAF and metastatic melanoma: Thus, low expression of RICTOR in metastatic melanoma is associated with a poor clinical outcome, and the gene expression signature of low RICTOR tumors indicates the activation of processes that are frequently associated with BRAF/MEKi resistance [6, 24, 25].